Trials / Unknown
UnknownNCT05843305
A Study of BPI-452080 in Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-452080 in Subjects With Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 87 (estimated)
- Sponsor
- Betta Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label Phase 1 study will evaluate the efficacy and safety of BPI-452080 in patients with Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BPI-452080 | Subjects will receive BPI-452080 until disease progression |
Timeline
- Start date
- 2023-04-28
- Primary completion
- 2025-03-25
- Completion
- 2025-10-31
- First posted
- 2023-05-06
- Last updated
- 2023-05-06
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05843305. Inclusion in this directory is not an endorsement.